Pharmacyclics LLC

ACTIVE

1000 Gateway Blvd, South San Francisco, California, United Stateswww.pharmacyclics.comSubsidiary607 employeesEstablished: 1991-01-01

Part of AbbVie, Inc.

Clinical Trials

116

62 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1991

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

72.4%

Phase 2

16.4%

Phase 3

9.5%

Trial Status Distribution

Active, not recruiting

53.5%

Completed

39.7%

Terminated

6.9%

Clinical Trials

Trials sponsored by this organization (116)

A Clinical Study of Rituximab with Ibrutinib Compared to Rituxumab Alone, and Subsequently of Ibrutinib Alone Compared to Placebo in Treatment Naïve Subjects with Follicular Lymphoma

Phase 1

Active, not recruiting

Feb 2021440 participants

Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

Phase 1

Active, not recruiting

Jan 202144 participants

Research study of Ibrutinib in Combination with Venetoclax in patients with Mantle Cell Lymphoma

Phase 1

Active, not recruiting

Jan 2019362 participants

Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

Phase 1

Active, not recruiting

Dec 201844 participants

Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

Phase 1

Active, not recruiting

Dec 201844 participants

Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

Phase 1

Active, not recruiting

Nov 201844 participants

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Phase 1

Completed

interventional

Nov 201859 participants

A Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Patients with New Onset Chronic Graft Versus Host Disease (cGVHD)

Phase 1

Active, not recruiting

Mar 2018193 participants

Page 1 of 15

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

Recent Approvals

News

No news articles found

Back to Organizations